AVEO Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own AVEO Pharmaceuticals Inc.
Polar Capital Funds Plc - Healthcare Opportunities Fund
4,280,406
3.52%
-2,472,260
0.73%
07/31/2018
Vanguard Total Stock Market Index Fund
3,004,743
2.47%
32,057
0%
07/31/2018
iShares Russell 2000 ETF
2,127,132
1.75%
-1,137
0.01%
09/06/2018
Vanguard Extended Market Index Fund
1,397,027
1.14%
-919
0.01%
07/31/2018
Polar Capital Funds Plc - Biotechnology Fund
800,000
0.66%
0
0.48%
07/31/2018
iShares Russell 2000 Growth ETF
593,450
0.49%
0
0.02%
09/06/2018
Fidelity Spartan Extended Market Index Fund
440,743
0.36%
0
0.01%
07/31/2018
iShares Russell 2000 Value ETF
389,859
0.32%
0
0.01%
09/06/2018
Bridgeway Ultra Small Company Market Fund
280,000
0.23%
0
0.19%
12/31/2017
iShares Micro Cap ETF
272,081
0.22%
0
0.07%
09/06/2018
| Address |
One Broadway
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.aveooncology.com |
| Updated |
07/08/2019 |
| AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. The company was founded by Ronald A. |
